Synthetic Biology and Biomanufacturing

Canada's synthetic biology sector is coalescing around academic hubs at the University of Toronto, McGill, and UBC, coordinated nationally by SynBio Canada. Toronto-based Genecis engineers microbes to produce biodegradable plastics (PHA) from organic waste streams, while university labs develop engineered organisms for producing fine chemicals, agricultural inputs, and therapeutic proteins. The sector spans applications from bio-based materials and sustainable agriculture to novel drug manufacturing and carbon capture through engineered organisms.

Synthetic biology matters because it represents a fundamental shift in manufacturing — programming biological systems to produce materials, chemicals, and medicines rather than relying on petrochemical synthesis or resource extraction. For Canada, synbio offers a path to higher-value biomanufacturing that leverages the country's strong life sciences research base and agricultural biomass feedstocks. The convergence of AI (for protein design and metabolic pathway optimization) with synthetic biology is particularly promising given Canada's AI strengths.

The strategic calculation for Canada is that biomanufacturing could become as important as digital technology in the coming decades. Countries that build the infrastructure, talent, and regulatory frameworks for synthetic biology will capture significant economic value. Canada has the academic foundation — its iGEM teams consistently rank among the world's best — but needs to accelerate the commercialization pipeline. The risk of inaction is that Canadian synbio talent follows the same pattern as AI talent: trained in Canada, commercialized elsewhere.